MOR vs. SMMT, EVO, CORT, RYTM, INDV, ALPN, MLTX, MRUS, ACAD, and HCM
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Summit Therapeutics (SMMT), Evotec (EVO), Corcept Therapeutics (CORT), Rhythm Pharmaceuticals (RYTM), Indivior (INDV), Alpine Immune Sciences (ALPN), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical preparations" industry.
Summit Therapeutics (NASDAQ:SMMT) and MorphoSys (NASDAQ:MOR) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 83.7% of Summit Therapeutics shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summit Therapeutics has a net margin of 0.00% compared to Summit Therapeutics' net margin of -80.07%. MorphoSys' return on equity of -87.45% beat Summit Therapeutics' return on equity.
Summit Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 125.99%. MorphoSys has a consensus price target of $11.78, suggesting a potential downside of 34.37%. Given MorphoSys' stronger consensus rating and higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than MorphoSys.
Summit Therapeutics has a beta of -1.21, suggesting that its stock price is 221% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
Summit Therapeutics received 259 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 56.91% of users gave Summit Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
MorphoSys has higher revenue and earnings than Summit Therapeutics. MorphoSys is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, MorphoSys had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for MorphoSys and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.74 beat MorphoSys' score of 0.44 indicating that MorphoSys is being referred to more favorably in the news media.
Summary
Summit Therapeutics beats MorphoSys on 10 of the 18 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
